Building on the unexpected outcomes of global IL‐17RA deficiency, Chandra and colleagues then explored the systemic impact of disrupted IL‐17A/IL‐17RA signaling in the intestine, focusing on both pancreatic and syngeneic murine glioma (GBM) tumors. The gene discussed is IL17A; the disease is central nervous system cancer.